HC Wainwright Weighs in on Taro Pharmaceutical Industries Ltd.’s Q1 2024 Earnings (NYSE:TARO)

Posted by on Jun 7th, 2023

Taro Pharmaceutical Industries Ltd. (NYSE:TARO – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Taro Pharmaceutical Industries in a research report issued to clients and investors on Monday, June 5th. HC Wainwright analyst R. Selvaraju expects that the company will earn $0.31 per share for the quarter. HC Wainwright also issued estimates for Taro Pharmaceutical Industries’ Q2 2024 earnings at $0.30 EPS, Q3 2024 earnings at $0.32 EPS, Q4 2024 earnings at $0.33 EPS and FY2024 earnings at $1.27 EPS.

Separately, StockNews.com raised Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Sunday, May 28th.

Taro Pharmaceutical Industries Price Performance

NYSE TARO opened at $39.03 on Tuesday. Taro Pharmaceutical Industries has a 1-year low of $22.89 and a 1-year high of $40.15. The business’s fifty day moving average price is $27.99 and its 200-day moving average price is $28.90. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 58.25 and a beta of 0.61.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Krensavage Asset Management LLC bought a new stake in shares of Taro Pharmaceutical Industries during the first quarter valued at approximately $15,611,000. Armistice Capital LLC boosted its holdings in Taro Pharmaceutical Industries by 49.6% in the third quarter. Armistice Capital LLC now owns 245,372 shares of the company’s stock valued at $7,356,000 after purchasing an additional 81,372 shares during the last quarter. Cowen AND Company LLC acquired a new position in shares of Taro Pharmaceutical Industries in the fourth quarter worth about $2,050,000. Norges Bank acquired a new position in shares of Taro Pharmaceutical Industries in the fourth quarter worth about $1,765,000. Finally, Brandes Investment Partners LP raised its position in shares of Taro Pharmaceutical Industries by 11.8% in the first quarter. Brandes Investment Partners LP now owns 462,356 shares of the company’s stock worth $11,244,000 after acquiring an additional 48,811 shares during the period. Hedge funds and other institutional investors own 11.45% of the company’s stock.

About Taro Pharmaceutical Industries

(Get Rating)

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.

Featured Articles

Earnings History and Estimates for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.